Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Breast cancer development in BRCA1/2 mutation carriers is a net consequence of cell-autonomous and cell nonautonomous factors which may serve as excellent targets for cancer prevention. In light of our previous data we sought to investigate the consequences of the BRCA-mutation carrier state on RANKL/osteoprotegerin (OPG) signalling. We analysed serum levels of RANKL, OPG, RANKL/OPG complex, oestradiol (E2), and progesterone (P) during menstrual cycle progression in 391 BRCA1/2-mutation carriers and 782 noncarriers. These studies were complemented by analyses of RANKL and OPG in the serum and mammary tissues of female cynomolgus macaques (n = 88) and serum RANKL and OPG in postmenopausal women (n = 150). BRCA-mutation carriers had lower mean values of free serum OPG in particular in BRCA1-mutation carriers (p = 0.018) compared with controls. Among BRCA1/2 mutation carriers, lower OPG levels were associated with germline mutation locations known to confer an increased breast cancer risk (p = 0.003). P is associated with low OPG levels in serum and tissue, particularly in BRCA-mutation carriers (rho = - 0.216; p = 0.002). Serum OPG levels were inversely correlated (rho = - 0.545, p < 0.001) with mammary epithelial proliferation measured by Ki67 expression and increased (p = 0.01) in postmenopause. The P-RANKL/OPG system is dysregulated in BRCA-mutation carriers. These and previously published data provide a strong rationale for further investigation of antiprogestogens or an anti-RANKL antibody such as denosumab for breast cancer prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cuzick, J., Sestak, I., Baum, M., Buzdar, A., Howell, A., Dowsett, M., & Forbes, J. F. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70257-6 · Cited by 1,674 · cited 1×
“selective oestrogen receptor modulators like tamoxifen or aromatase inhibitors), although successful for primary prevention and adjuvant treatment in oestrogen receptor-positive cancers (Cuzick et al., 2015; Cuzick et al., 2014; Forbes et al., 2008), are unlikely to be successful in BRCA1-mutation carriers.”
BackgroundDomchek, S. M. (2010) · JAMA · doi:10.1001/jama.2010.1237 · Cited by 1,494 · cited 4×
“, 2005), recent evidence linking BRCA-associated risk and hormonal factors (Domchek et al., 2010; Dubeau, 2015) suggests an interplay between cell-autonomous and cell nonautonomous factors in BRCAmutation carriers.”
BackgroundInfluentialRole of RANK ligand in mediating increased bone resorption in early postmenopausal women
Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17215 · Cited by 825 · cited 2×
“However, serum levels of RANKL do not appear to reflect local increases at the tissue level, including breast (this study) and bone (Eghbali-Fatourechi et al., 2003).”
BackgroundCuzick, J., Sestak, I., Forbes, J. F., Dowsett, M., Knox, J., Cawthorn, S., Saunders, C., Roche, N., Mansel, R. E., von Minckwitz, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62292-8 · Cited by 590 · cited 2×
“selective oestrogen receptor modulators like tamoxifen or aromatase inhibitors), although successful for primary prevention and adjuvant treatment in oestrogen receptor-positive cancers (Cuzick et al., 2015; Cuzick et al., 2014; Forbes et al., 2008), are unlikely to be successful in BRCA1-mutation carriers.”
Background(2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70301-2 · Cited by 399 · cited 2×
“…in postmenopausal women (Fourkala et al., 2012; Key et al., 2011), but documenting a the CC BY license (http://creativecommons.org/licenses/by/4.0/). premenopausal link is challenging due to hormonal fluctuations associated with menstrual cycle progression (Key et al., 2013; Kaaks et al., 2014).”
BackgroundInfluential
Cited by
Personalized early detection and prevention of breast cancer: ENVISION consensus statement
Pashayan, N., Antoniou, A. C., Ivanus, U., Esserman, L. J., Easton, D. F., French, D., Sroczynski, G., Hall, P., Cuzick, J., Evans, D. G., et al. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0388-9 · Cited by 438
Self-citationProgesterone and Breast Cancer
Trabert, B., Sherman, M. E., Kannan, N., & Stanczyk, F. Z. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnz001 · Cited by 271
RANKL/RANK: from bone loss to the prevention of breast cancer
Sigl, V., Jones, L. P., & Penninger, J. M. (2016) · Open Biology · doi:10.1098/rsob.160230 · Cited by 76
Can we prevent BRCA1-associated breast cancer by RANKL inhibition?
Kotsopoulos, J., Singer, C., & Narod, S. A. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-016-4029-z · Cited by 37
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation
Kotsopoulos, J., Gronwald, J., Huzarski, T., Aeilts, A., Randall Armel, S., Karlan, B., Singer, C. F., Eisen, A., Tung, N., Olopade, O., et al. (2023) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-06991-3 · Cited by 26
Metadata
- Authors
- Widschwendter, M., Burnell, M., Fraser, L., Rosenthal, A. N., Philpott, S., Reisel, D., Dubeau, L., Cline, M., Pan, Y., Yi, P.-C., Gareth Evans, D., Jacobs, I. J., Menon, U., Wood, C. E., & Dougall, W. C.
- Venue
- EBioMedicine
- Publisher
- Elsevier BV
- Published
- 2015-10
- Volume
- 2
- Issue
- 10
- Pages
- 1331-1339
- ISSN
- 2352-3964 (ISSN-L)
- OpenAlex
- W2164699140
- Cited by
- 65
- References
- 5
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. https://app.cochat.ai/papers/10.1016/j.ebiom.2015.08.037
- The paper
- Widschwendter, M., Burnell, M., Fraser, L., Rosenthal, A. N., Philpott, S., Reisel, D., Dubeau, L., Cline, M., Pan, Y., Yi, P.-C., Gareth Evans, D., Jacobs, I. J., Menon, U., Wood, C. E., & Dougall, W. C. (2015). Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine. https://doi.org/10.1016/j.ebiom.2015.08.037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.